Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Clinical and molecular details of individuals with dual molecular diagnosesPatientAgeGenderHPOGeneTranscript(NM)chromosomal locationcDNAAA ChangeZygosityInherited FromAssociated DiseaseInheritance ModeVariant Classification18 years and 10 monthsMaleHypertelorism (HP:0000316), Joint contracture(HP:0034392),Ulnar claw(HP:0001178), Shield chest(HP:0000914),Café-au-lait spot (HP:0000957), Fever (HP:0001945), Abdominal distension (HP:0003270), Short stature (HP:0004322), Cough (HP:0012735), Night sweats (HP:0030166)ABCD1NM_000033chrX:153,001,686 to 153,001,686c.1202G > Ap.(Arg401Gln)HemizygousmaternalAdrenoleukodystrophy; ALD (OMIM: 300100)X-linkedLikely PathogenicCHRNGNM_005199chr2:233406161 to 233,406,161c.428 C > Gp.(Pro143Arg)HeterozygousmaternalLethal Multiple Pterygium Syndrome; LMPS (OMIM: 253290)|Escobar Variant Multiple Pterygium Syndrome; EVMPS (OMIM: 265000)ARPathogenicchr2:233408088 to 233,408,089c.897_912dupp.(Ile305Profs*98)HeterozygouspaternalLikely Pathogenic28 yearsMaleIntellectual disability (HP:0001249), Seizures (HP:0001250), Abnormal EEG (HP:0002353), Febrile seizures (HP:0002373), Genu valgum (HP:0002857), Myopathy (HP:0003198), Difficulty climbing stairs (HP:0003551), Muscular dystrophy (HP:0003560), Motor developmental delay (HP:0031936), Finger flexion (HP:0040019), Clinodactyly of the 5th finger(HP:0004209)CSNK2A1NM_177559chr20:472926 to 472,926c.593 A > Gp.Lys198ArgHeterozygouspaternalOkur-Chung Neurodevelopmental Syndrome (OMIM: 617062)ADPathogenicDMDNM_004006chrX:32,519,871 to 32,563,451loss(EXON:17 to 19)44 KHemizygousmaternalBecker Muscular Dystrophy (OMIM: 300376)|Duchenne Muscular Dystrophy/Progressive Pseudohypertrophic Muscular Dystrophy (OMIM: 310200)X-linkedLikely Pathogenic32 years and 6 monthsFemaleAbnormal stature (HP:0000002), Thin vermilion of the upper lip (HP:0000219), Long philtrum (HP:0000343), Telecanthus (HP:0000506), Jaundice (HP:0000952), Global developmental delay (HP:0001263), Prominent forehead (HP:0011220), Small hands (HP:0200055)KIDINS220NM_001348738chr2:8943262 to 8,943,262c.604-5T > GHeterozygousde novoSpastic Paraplegia, Intellectual Disability, Nystagmus, and Obesity (OMIM: 617296)ADLikely PathogenicARID2NM_152641chr12:46123619 to 46,254,732loss1(EXON:1 to 16)131,114 bpHeterozygousde novoCoffin-Siris Syndrome Type 6; CSS6 (OMIM: 617808)ADPathogenic44 years and 8 monthsMaleEpicanthus (HP:0000286), Low anterior hairline (HP:0000294), Long philtrum (HP:0000343), Posteriorly rotated ears (HP:0000358), Protruding ears (HP:0000411), Heavy eyebrows (HP:0000574), Long palpebral fissure (HP:0000637), Autism/Autistic disorder (HP:0000717), Delayed speech and language development (HP:0000750), Intellectual disability (HP:0001249), Hypotonia (HP:0001252), Global developmental delay (HP:0001263), Neurogenic language disorder (HP:0002167), Short stature (HP:0004322), Widely spaced nipples (HP:0006610), Ectropion of lower eyelid (HP:0007651), Curvature of the middle phalanx of the 5th finger (HP:0009173), Short 5th finger (HP:0009237), Broad chin (HP:0012802), Irregular dentition (HP:0040079)TBL1XR1NM_024665chr3:176756100 to 176,756,100c.1047 + 1G > CHeterozygousde novoPierpont Syndrome (OMIM: 602342)|Mental Retardation, Autosomal Dominant 41; MRD41 (OMIM: 616944)ADPathogenicPTCHD1NM_173495chrX:23,412,098 to 23,412,098c.2463T > Ap.Cys821TerHemizygousde novoX-linked Autism Susceptibility 4 (OMIM: 300830)X-linkedPathogenic51 year and 1 monthMaleRenal enlargement (HP:0000105), Renal cysts (HP:0000107), High palate (HP:0000218), Abnormal forehead (HP:0000290), Delayed speech and language development (HP:0000750), Simian crease (HP:0000954), Global developmental delay (HP:0001263), Motor delay (HP:0001270), Decreased liver function (HP:0001410), Growth retardation (HP:0001510), Patent foramen ovale (HP:0001655), Gross motor developmental delay (HP:0002194), Abnormal electroencephalogram (HP:0002353), Language disorder (HP:0002357), Hyperphenylalaninemia (HP:0004923), Cerebral hypoplasia (HP:0006872), Lateral ventricular enlargement (HP:0006956), High anterior hairline (HP:0009890), Fine motor developmental delay (HP:0010862), Abnormal acetylcarnitine metabolism (HP:0012071), Hypoglycinemia (HP:0012277), Subarachnoid space widening (HP:0012704), Movement disorder (HP:0100660), Tongue thrusting habit (HP:0100703), Hypotyrosinemia (HP:0500133), Hypoprolinemia (HP:0500139), Hypoalaninemia (HP:0500154)PKD1NM_001009944chr16:2161098 to 2,161,098c.4070delTp.Leu1357fsTer9HeterozygouspaternalPolycystic Kidney Disease Type 1 with or without Polycystic Liver Disease (OMIM: 173900)ADLikely PathogenicNANAchr15:1-102531392:upd1Paternal uniparental disomy of chromosome 15NANAAngelman syndrome (OMIM:105830)Pathogenic617 yearsFemaleDental abnormalities (HP:0000164), Myopia (HP:0000545), Intellectual disability (HP:0001249), Growth retardation (HP:0001510), Abnormal weight (HP:0004323), Short 5th finger (HP:0009237), Motor developmental delay (HP:0031936)RERENM_012102chr1:8416246 to 8,416,246c.4400G > Ap.(Arg1467His)Heterozygousde novoNeurodevelopmental Disorder with or without Abnormalities of the Brain, Eye, or Heart (OMIM: 616975)ADLikely PathogenicNANAchr7:72717592 to 74,148,323:loss1Heterozygousde novoADPathogenic78 monthsMaleThin vermilion border (HP:0000233), Low anterior hairline (HP:0000294), Short philtrum (HP:0000322), Hypotonia (HP:0001252), Global developmental delay (HP:0001263), Muscle weakness (HP:0001324), Growth retardation (HP:0001510), Respiratory distress (HP:0002098), Short mandibular ramus (HP:0003778), Motor developmental delay (HP:0031936)DVL1NM_001330311chr1:1273664 to 1,273,664c.1492G > Cp.Gly498ArgMosaicde novoAutosomal Dominant Robinow Syndrome Type 2 (OMIM: 616331)ADLikely PathogenicNKX2-1NM_003317chr14:36988301 to 36,988,302c.263_c.264insAp.Asn88fsTer321HeterozygousmaternalBenign Hereditary Chorea (OMIM: 118700)ADLikely Pathogenic81 year and 4 monthsFemaleGlobal developmental delay (HP:0001263), Abnormal liver function (HP:0001410), Growth retardation (HP:0001510), Abnormal heart morphology (HP:0001627), Fever (HP:0001945), Pneumonia (HP:0002090), Hyperuricemia (HP:0002149), Lymphadenopathy (HP:0002716), Elevated liver transaminases (HP:0002910), Decreased plasma carnitine (HP:0003234), Tricuspid regurgitation (HP:0005180), Cough (HP:0012735), Motor developmental delay (HP:0031936), Pleural thickening (HP:0031944), Bronchial stenosis (HP:4000007)SLC22A5NM_003060chr5:131705925 to 131,705,926c.261_c.262insACCGGCTCGCCp.Ile89fsTer45HeterozygouspaternalPrimary Carnitine Deficiency (OMIM: 212140)ARPathogenicchr5:131722736 to 131,722,736c.844 C > Tp.Arg282Ter,276HeterozygousmaternalPathogenicNANAchr17:15133095 to 15,472,344:gain1Heterozygousde novoADPathogenic914 years and 7 monthsFemaleGonadal dysgenesis (HP:0000133), Delayed speech and language development (HP:0000750), Hypothyroidism (HP:0000821), Intellectual disability (HP:0001249), Global developmental delay (HP:0001263), Motor delay (HP:0001270), Excessive thyrotropin production (HP:0002925), Significant delay in bone age (HP:0003799), Short stature (HP:0004322), Female pubertal developmental disorder (HP:0008647), Abnormal uterine morphology (HP:0031105), Vitamin D deficiency (HP:0100512)ASXL1NM_015338chr20:31019280 to 31,019,280c.875 A > Gp.Asp292GlyHeterozygousde novoBohring-Opitz Syndrome/ “C-like” Syndrome (OMIM: 605039)|Myelodysplastic Syndrome Susceptibility; MDS (OMIM: 614286)ADLikely PathogenicSOX10NM_006941chr22:38369948 to 38,369,948c.957delGp.Leu320Trpfs*37Heterozygousde novoPeripheral Demyelinating Neuropathy, Central Dysmyelination, Waardenburg Syndrome, and Hirschsprung Disease/PCWH Syndrome (OMIM: 609136)|Waardenburg Syndrome Type 4 C (OMIM: 613266)|Waardenburg Syndrome Type 2E (OMIM: 611584)ADPathogenic101 year and 3 monthsMaleHydrocephalus (HP:0000238), Short philtrum (HP:0000322), Micrognathia (HP:0000347), Hypotonia (HP:0001252), Muscle weakness (HP:0001324), Weak cry (HP:0001612), Babinski sign (HP:0003487), Curved fingers (HP:0004095), Motor developmental delay (HP:0031936), Increased head circumference (HP:0040194), Cognitive impairment (HP:0100543)MYH2NM_017534chr17:10430037 to 10,430,037c.4066G > Tp.(Glu1356Ter,586)HeterozygousmaternalCongenital Myopathy Type 6 with Ophthalmoplegia; CMYP6 (OMIM: 605637)ADLikely PathogenicMECP2NM_001110792chrX:153,296,354 to 153,296,354c.961 C > Tp.(Arg321Trp)HemizygousmaternalX-linked Autism Susceptibility 3; AUTSX3 (OMIM: 300496)|X-linked Intellectual Developmental Disorder, Lubs Type; MRXSL (OMIM: 300260)|Neonatal Severe Encephalopathy Due to MECP2 Mutation (OMIM: 300673)|X-linked Intellectual Developmental Disorder 13; MRXS13 (OMIM: 300055)|Rett Syndrome; RTT (OMIM: 312750)X-linkedPathogenic1111 years and 9 monthsMaleGait disturbance (HP:0001288), Abnormal calf muscles (HP:0001430), Foot abnormalities (HP:0001760), Achilles tendon contracture (HP:0001771), Hypertriglyceridemia (HP:0002155), Hyperhomocysteinemia (HP:0002160), Elevated liver transaminases (HP:0002910), Increased serum creatine phosphokinase (HP:0003236), Hypophosphatasia (HP:0003282), Increased serum pyruvate (HP:0003542), Muscular dystrophy (HP:0003560), Restricted ankle joint movement (HP:0010505), Decreased serum creatinine (HP:0012101), Unsteady gait (HP:0012651), Increased lactate dehydrogenase activity (HP:0025435), Increased circulating myoglobin concentration (HP:0033438)RRAS2NM_012250chr11:14380347 to 14,380,348c.70_78dupp.(Gly24_Gly26dup)HeterozygousunknownNoonan Syndrome Type 12; NS12 (OMIM: 618624)ADPathogenicDMDNM_004006chrX:31,947,712 to 31,950,344loss(EXON:46 to 47)Hemizygousde novoDuchenne Muscular Dystrophy; DMD (OMIM: 310200)|Dilated Cardiomyopathy Type 3B; CMD3B (OMIM: 302045)|Becker Muscular Dystrophy; BMD (OMIM: 300376)X-linkedPathogenic1215 years and 4 monthsMaleIrritability (HP:0000713), Dystonia (HP:0001332), Memory impairment (HP:0002354), Abnormal posture (HP:0002533), Involuntary movements (HP:0004305), Extrapyramidal movement disorder (HP:0007308), Fine motor developmental delay (HP:0010862), Cognitive impairment (HP:0100543)GNALNM_182978chr18:11752885 to 11,752,888c.410_413delAACAp.(Lys137Argfs*2)HeterozygouspaternalDystonia Type 25; DYT25 (OMIM: 615073)ADLikely PathogenicSGCENM_003919chr7:94230140 to 94,230,140c.855T > Gp.(Tyr285Ter,153)HeterozygouspaternalMyoclonus-Dystonia Syndrome Type 11; DYT11 (OMIM: 159900)ADLikely Pathogenic132 monthsMaleCryptorchidism (HP:0000028), Hydrocele testis (HP:0000034), High palate (HP:0000218), Epicanthus (HP:0000286), Micrognathia (HP:0000347), Esotropia (HP:0000565), Thumb adduction (HP:0001181), Hypotonia (HP:0001252), Spastic paraplegia (HP:0001258), Global developmental delay (HP:0001263), Patent foramen ovale (HP:0001655), Gross motor developmental delay (HP:0002194), Subependymal cysts (HP:0002416), Neonatal hyperbilirubinemia (HP:0003265), Abdominal distension (HP:0003270), Abnormal weight (HP:0004323), Hyperreflexia of the knee tendon (HP:0007083), Bilateral cryptorchidism (HP:0008689), Fifth toe abnormality (HP:0010322), Prominent forehead (HP:0011220), Mongolian spot (HP:0011369), Cyanotic macule (HP:0033832)NR0B1NM_000475chrX:30,322,932 to 30,322,932c.1177G > Tp.(Gly393Cys)Mosaicde novoCongenital Adrenal Hypoplasia; AHC (OMIM: 300200)|46,XY Sex Reversal 2; SRXY2 (OMIM: 300018)X-linkedLikely PathogenicCOL1A1NM_000088chr17:48263829 to 48,263,829c.3854 A > Gp.(Asp1285Gly)Heterozygousde novoOsteogenesis Imperfecta-Ehlers-Danlos Syndrome 1; OIEDS1 (OMIM: 619115)|Ehlers-Danlos Syndrome, Arthrochalasia Type 1; EDSARTH1 (OMIM: 130060)|Osteogenesis Imperfecta Type 2; OI2 (OMIM: 166210)|Osteogenesis Imperfecta Type 1; OI1 (OMIM: 166200)|Osteogenesis Imperfecta Type 3; OI3 (OMIM: 259420)|Caffey Disease; CAFYD (OMIM: 114000)|Osteoporosis (OMIM: 166710)|Osteogenesis Imperfecta Type 4; OI4 (OMIM: 166220)ADPathogenic144 years and 11 monthsFemaleHypertelorism (HP:0000316), Café-au-lait spot (HP:0000957), Fever (HP:0001945), Abdominal distension (HP:0003270), Short stature (HP:0004322), Cough (HP:0012735), Night sweats (HP:0030166)ACANNM_001369268chr15:89382006 to 89,382,007c.186_187insCTGTGACCp.(Ala63Leufs*2)HeterozygouspaternalSpondyloepiphyseal Metaphyseal Dysplasia, Aggrecan Type; SEMDAG (OMIM: 612813)|Short Stature with Advanced Bone Age, with or without Early-Onset Osteoarthritis and/or Osteochondritis Dissecans; SSOAOD (OMIM: 165800)|Spondyloepiphyseal Dysplasia, Kimberley Type; SEDK (OMIM: 608361)ADLikely PathogenicPOLENM_006231chr12:133226069 to 133,226,071c.3832_3834delAAGp.(Lys1278del)HeterozygousmaternalIntrauterine Growth Retardation, Metaphyseal Dysplasia, Adrenal Hypoplasia Congenita, Genital Anomalies, and Immunodeficiency; IMAGEI (OMIM: 618336)|Facial Dysmorphism, Immunodeficiency, Livedo, and Short Stature (FILS Syndrome); FILS (OMIM: 615139)ARLikely Pathogenicchr12:133220132 to 133,220,133c.4306dupp.(Arg1436Profs*14)HeterozygouspaternalLikely PathogenicNA: Not Applicable

Source: Diagnostic yield. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Fourteen patients were confirmed to have dual molecular diagnoses.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Clinical and genetic spectrum of dual rare genetic diseases revealed by whole-exome sequencing in 14 pediatric patients

Study design awaiting verification · Orphanet Journal of Rare Diseases · 2026

Original publication title

Clinical and genetic spectrum of dual rare genetic diseases revealed by whole-exome sequencing in 14 pediatric patients

Minjun Zhao; Fuwei Li; Xiangpeng Lu; Hong Zheng; Xilong Du

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Dual molecular diagnoses occur in approximately 3.8% of molecularly diagnosed patients and frequently involve de novo dominant variants. WES effectively detects multiple variant types (including SNV, CNV, exon deletions, UPD, and mosaicism) providing crucial insights for precise diagnosis, management, and genetic counseling in children with complex phenotypes.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To investigate the clinical and genetic spectrum of dual rare genetic diseases in pediatric patients and to assess the diagnostic utility of WES in detecting diverse variant types.

Source: Objective

Abstract: What methods does the paper describe?

A retrospective analysis was conducted on 872 children with suspected rare genetic disorders who underwent proband or trio-based WES from January 2019 to February 2025. Variants were classified according to American College of Medical Genetics and Genomics(ACMG) guidelines. Dual diagnoses were confirmed when two independent pathogenic or likely pathogenic variants, each explaining part of the phenotype, were identified.

Source: Methods

Abstract: Results

Among 872 patients, 370 (42.4%) received a molecular diagnosis, and 14 (3.8%) were confirmed with dual molecular diagnoses. Autosomal dominant (AD) disorders were most frequent (85.7%), de novo variants represented 57.14% (8 out of 14 cases). Six patients (42.9%) harbored combinations of single nucleotide variant (SNV) and other variant types, including exon deletions, paternal uniparental disomy (UPD15). Clinically, 14.3% of cases were phenotypically distinct, while 85.7% were phenotypically overlapping.

Source: Results

Abstract: Conclusion

Dual molecular diagnoses occur in approximately 3.8% of molecularly diagnosed patients and frequently involve de novo dominant variants. WES effectively detects multiple variant types (including SNV, CNV, exon deletions, UPD, and mosaicism) providing crucial insights for precise diagnosis, management, and genetic counseling in children with complex phenotypes.

Source: Conclusion
Authors’ abstract

Background

Dual molecular diagnoses, defined as the coexistence of pathogenic variants in two distinct disease-causing genes, challenge the traditional single-gene model of Mendelian inheritance. With the advent of whole-exome sequencing (WES), such complex genotypes are increasingly recognized.

Objective

To investigate the clinical and genetic spectrum of dual rare genetic diseases in pediatric patients and to assess the diagnostic utility of WES in detecting diverse variant types.

Methods

A retrospective analysis was conducted on 872 children with suspected rare genetic disorders who underwent proband or trio-based WES from January 2019 to February 2025. Variants were classified according to American College of Medical Genetics and Genomics(ACMG) guidelines. Dual diagnoses were confirmed when two independent pathogenic or likely pathogenic variants, each explaining part of the phenotype, were identified.

Results

Among 872 patients, 370 (42.4%) received a molecular diagnosis, and 14 (3.8%) were confirmed with dual molecular diagnoses. Autosomal dominant (AD) disorders were most frequent (85.7%), de novo variants represented 57.14% (8 out of 14 cases). Six patients (42.9%) harbored combinations of single nucleotide variant (SNV) and other variant types, including exon deletions, paternal uniparental disomy (UPD15). Clinically, 14.3% of cases were phenotypically distinct, while 85.7% were phenotypically overlapping.

Conclusion

Dual molecular diagnoses occur in approximately 3.8% of molecularly diagnosed patients and frequently involve de novo dominant variants. WES effectively detects multiple variant types (including SNV, CNV, exon deletions, UPD, and mosaicism) providing crucial insights for precise diagnosis, management, and genetic counseling in children with complex phenotypes.

Publication and source details

Original title: Clinical and genetic spectrum of dual rare genetic diseases revealed by whole-exome sequencing in 14 pediatric patients

Minjun Zhao; Fuwei Li; Xiangpeng Lu; Hong Zheng; Xilong Du

Orphanet Journal of Rare Diseases · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of ChinaGrant No. 82274579Grant No. 82104929Lu Xiangpeng Zheng Hong http://dx.doi.org/10.13039/100018925Health Commission of Henan ProvinceGrant No. LHGJ20240674Zheng Hong

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:40:05.393784+00:00

DOI: 10.1186/s13023-026-04462-8 · PMC13591918